Valuation: 89bio, Inc.

Market Cap 2.31B 2.03B 1.92B 1.74B 3.27B 222B 3.29B 22.99B 8.88B 113B 8.67B 8.48B 363B P/E 2023
-5.59x
P/E 2024 -2.23x
Enterprise Value 1.91B 1.68B 1.59B 1.44B 2.7B 183B 2.72B 18.98B 7.33B 93.37B 7.16B 7B 300B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99.46%
Yield 2023 *
-
Yield 2024 -
1 year 14.67
Extreme 14.67
14.92
3 years 4.16
Extreme 4.16
16.63
5 years 2
Extreme 2
22.93
10 years 2
Extreme 2
47.25
Manager TitleAgeSince
Chief Executive Officer 60 2018-05-31
Director of Finance/CFO 49 2019-06-30
Chief Operating Officer 55 2024-08-04
Date Insider Type Main position Quantity % Market Cap. Importance
10/30/25 Tender

Founder

480,180 0.3234%
10/30/25
RA Capital Management LP
Issuer saleCompany 24,401,214 16.4326%
10/30/25 Free

Chief Technology Officer

1,357,397 0.9141%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%+0.95%-3.89% 2.31B
-0.37%+1.12%+57.21%+84.56% 72.26B
-0.07%-2.70%+37.74%+86.90% 60.24B
+0.75%+6.06%+36.71%+19.87% 27.73B
-0.14%-2.75%-14.13%+356.79% 25.73B
+0.57%+1.10%+1.02%-2.89% 24.75B
+1.10%+1.86%+25.07%-8.51% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.36%+2.01%+49.51%+160.70% 14.41B
-2.53%-1.39%-6.38%+469.36% 14.23B
Average -0.20%-0.10%+33.80%+148.60% 27.75B
Weighted average by Cap. -0.12%-1.07%+37.82%+125.00%

Financials

2023 2024
Net sales - -
Net income -142M -125M -118M -107M -201M -13.65B -203M -1.42B -547M -6.96B -534M -522M -22.38B -367M -323M -305M -277M -520M -35.24B -523M -3.66B -1.41B -17.98B -1.38B -1.35B -57.78B
Net Debt -552M -485M -459M -416M -782M -52.96B -786M -5.49B -2.12B -27.03B -2.07B -2.03B -86.85B -402M -354M -335M -304M -570M -38.63B -573M -4.01B -1.55B -19.71B -1.51B -1.48B -63.34B
Logo 89bio, Inc.
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone.
Employees
93
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. ETNB Stock